97901-22-9
Chemical Structure
Nafagrel hydrochloride
Synonym(s): DP-1904
- CAS No.: 97901-22-9
- Formula:C15H17ClN2O2
- Molecular Weight:292.76
IUPAC Name: 6-((1H-imidazol-1-yl)methyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid hydrochloride
InChIKey: DRWRJLPMUWWEHY-UHFFFAOYSA-N
SMILES: OC(C1=CC=C(CC(CN2C=CN=C2)CC3)C3=C1)=O.Cl
Biological Activity: Nafagrel hydrochloride is a Thromboxane A2 synthase inhibitor. Nafagrel hydrochloride inhibits the production of Thromboxane A2 and increases the production of Prostaglandin I2 (HY-A0126A). Nafagrel hydrochloride prevents thrombotic material accumulation in acute arterial thrombosis models. Nafagrel hydrochloride can be used in research on peripheral vascular disease, restenosis after PTCA, and lupus nephritis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nafagrel hydrochloride | Nafagrel hydrochloride is a Thromboxane A2 synthase inhibitor. Nafagrel hydrochloride inhibits the production of Thromboxane A2 and increases the production of Prostaglandin I2 (HY-A0126A). Nafagrel hydrochloride prevents thrombotic material accumulation in acute arterial thrombosis models. Nafagrel hydrochloride can be used in research on peripheral vascular disease, restenosis after PTCA, and lupus nephritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Geiger J, et al. Inhibitors of platelet signal transduction as anti-aggregatory drugs. Expert opinion on investigational drugs. 2001 May;10(5):865-90. [Content Brief]
- [2]. Herrman J P R, et al. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the Holy Grail?(Part I)[J]. Drugs, 1993, 46(1): 18-52.
- [3]. Kaneko N, et al. Production of thromboxane A2 and prostaglandin i2 affected by interaction of heat aggregated IgG, endothelial cells, and platelets in lupus nephritis. The Journal of rheumatology. 2002 Oct;29(10):2106-13.
